

## SPECIALTY GUIDELINE MANAGEMENT

### TORISEL (temsirolimus)

#### POLICY

##### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

###### A. FDA-Approved Indications

Torisel is indicated for the treatment of advanced renal cell carcinoma

###### B. Compendial Uses

1. Endometrial carcinoma
2. Soft tissue sarcoma subtypes:
  - Perivascular epithelioid cell tumors (PEComa)
  - Recurrent angiomyolipoma
  - Lymphangioliomyomatosis

All other indications are considered experimental/investigational and are not a covered benefit.

##### II. CRITERIA FOR INITIAL APPROVAL

###### A. **Renal Cell Carcinoma (RCC)**

Authorization of 12 months may be granted to members who are prescribed Torisel for the treatment of relapsed or unresectable RCC.

###### B. **Endometrial Carcinoma**

Authorization of 12 months may be granted to members who are prescribed Torisel for the treatment of endometrial carcinoma.

###### C. **Soft Tissue Sarcoma**

Authorization of 12 months may be granted to members prescribed Torisel for the treatment of any of the following subtypes of soft tissue sarcoma:

1. Perivascular epithelioid cell (PEComa)
2. Angiomyolipoma
3. Lymphangioliomyomatosis

##### III. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

##### IV. REFERENCES

1. Torisel [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc.; February 2015.
2. The NCCN Drugs & Biologics Compendium™ © 2016 National Comprehensive Cancer Network, Inc. <http://www.nccn.org>. Accessed June 28, 2016. [https://www.nccn.org/professionals/drug\\_compendium/content/contents.asp](https://www.nccn.org/professionals/drug_compendium/content/contents.asp).
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. Version 3.2016. Accessed August 2, 2016. [https://www.nccn.org/professionals/physician\\_gls/pdf/kidney.pdf](https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf).

4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms. Version 2.2016. Accessed August 2, 2016. [https://www.nccn.org/professionals/physician\\_gls/pdf/uterine.pdf](https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf).
5. Oza AM, Elit L, Tsao MS, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. *J Clin Oncol*. 2011;29(24):3278-85.
6. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma. Version 2.2016. Accessed August 2, 2016. [https://www.nccn.org/professionals/physician\\_gls/pdf/sarcoma.pdf](https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf).
7. Benson C, Vitfell-Rasmussen J, Maruzzo M, et al. A retrospective study of patients with malignant PEComa receiving treatment with sirolimus or temsirolimus: the Royal Marsden Hospital experience. *Anticancer Res* 2014;34:3663-8.